Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Immunapen
- Development stage
- Unknown
- Lead developer
- Medolife Rx
- Modality
- Peptides
- Administration
- Oral
01
Overview
Immunapen is an over-the-counter nutraceutical homeopathic oral solution developed by Medolife Rx that contains a patented polarized formulation of *Rhopalurus princeps* scorpion venom together with silica. The product is described by its developer as an immune-support and energy-boosting formulation derived from the proprietary scorpion-venom-based formulation used in Escozine, with proposed activity attributed to small venom peptides that reportedly can cross the blood-brain barrier and modulate ion channels including chloride, sodium, potassium, and calcium channels. Its claimed mechanism and disease-directed therapeutic effects remain promotional and nonstandard rather than established as a conventional pharmaceutical mechanism in regulated drug development.
- Brand names
- Immunapen
Beyond the preview
Go deeper on Immunapen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunapen.